

MDACC board review course: Gastric, esophageal, HCC (Harry H. Yoon)

References

- (1993). An international association between *Helicobacter pylori* infection and gastric cancer. The EUROGAST Study Group. *Lancet* 341, 1359-1362.
- (2014). Comprehensive molecular characterization of gastric adenocarcinoma. *Nature* 513, 202-209.
- Allum, W.H., Stenning, S.P., Bancewicz, J., Clark, P.I., and Langley, R.E. (2009). Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 27, 5062-5067.
- Bang, Y.J., Van Cutsem, E., Feyereislova, A., Chung, H.C., Shen, L., Sawaki, A., Lordick, F., Ohtsu, A., Omuro, Y., Satoh, T., *et al.* (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. *Lancet* 376, 687-697.
- Bedenne, L., Michel, P., Bouche, O., Milan, C., Mariette, C., Conroy, T., Pezet, D., Rouillet, B., Seitz, J.F., Herr, J.P., *et al.* (2007). Chemoradiation followed by surgery compared with chemoradiation alone in squamous cancer of the esophagus: FFCD 9102. *J Clin Oncol* 25, 1160-1168.
- Bruix, J., and Sherman, M. (2011). Management of hepatocellular carcinoma: an update. *Hepatology* 53, 1020-1022.
- Bruix, J., Takayama, T., Mazzaferro, T., Chau, G.-Y., Yang, J., Kudo, M., Cai, J., Poon, R.T.-P., Han, K.-H., Tak, W.-Y., *et al.* (2014). STORM: A phase III randomized, double-blind, placebo-controlled trial of adjuvant sorafenib after resection or ablation to prevent recurrence of hepatocellular carcinoma (HCC). *J Clin Oncol* 30, abstr 6.
- Conroy, T., Galais, M.P., Raoul, J.L., Bouche, O., Gourgou-Bourgade, S., Douillard, J.Y., Etienne, P.L., Boige, V., Martel-Lafay, I., Michel, P., *et al.* (2014). Definitive chemoradiotherapy with FOLFOX versus fluorouracil and cisplatin in patients with oesophageal cancer (PRODIGE5/ACCORD17): final results of a randomised, phase 2/3 trial. *The Lancet Oncology* 15, 305-314.
- Cristescu, R., Lee, J., Nebozhyn, M., Kim, K.M., Ting, J.C., Wong, S.S., Liu, J., Yue, Y.G., Wang, J., Yu, K., *et al.* (2015). Molecular analysis of gastric cancer identifies subtypes associated with distinct clinical outcomes. *Nat Med* 21, 449-456.
- Cunningham, D., Allum, W.H., Stenning, S.P., Thompson, J.N., Van de Velde, C.J., Nicolson, M., Scarffe, J.H., Loft, F.J., Falk, S.J., Iveson, T.J., *et al.* (2006). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. *N Engl J Med* 355, 11-20.
- Diaz-Nieto, R., Orti-Rodriguez, R., and Winslet, M. (2013). Post-surgical chemotherapy versus surgery alone for resectable gastric cancer. *The Cochrane database of systematic reviews* 9, CD008415.
- Ford, H.E., Marshall, A., Bridgewater, J.A., Janowitz, T., Coxon, F.Y., Wadsley, J., Mansoor, W., Fyfe, D., Madhusudan, S., Middleton, G.W., *et al.* (2014). Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial. *The Lancet Oncology* 15, 78-86.
- Fuchs, C.S., Tomasek, J., Yong, C.J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L.V., Aprile, G., Ferry, D.R., *et al.* (2014). Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. *Lancet* 383, 31-39.

- Harnois, D.M., Steers, J., Andrews, J.C., Rubin, J.C., Pitot, H.C., Burgart, L., Wiesner, R.H., and Gores, G.J. (1999). Preoperative hepatic artery chemoembolization followed by orthotopic liver transplantation for hepatocellular carcinoma. Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society 5, 192-199.
- Herskovic, A., Martz, K., al-Sarraf, M., Leichman, L., Brindle, J., Vaitkevicius, V., Cooper, J., Byhardt, R., Davis, L., and Emami, B. (1992). Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326, 1593-1598.
- Huang, J.Q., Sridhar, S., Chen, Y., and Hunt, R.H. (1998). Meta-analysis of the relationship between Helicobacter pylori seropositivity and gastric cancer. Gastroenterology 114, 1169-1179.
- Jemal, A., Bray, F., Center, M.M., Ferlay, J., Ward, E., and Forman, D. (2011). Global cancer statistics. CA Cancer J Clin 61, 69-90.
- Jemal, A., Siegel, R., Ward, E., Hao, Y., Xu, J., and Thun, M.J. (2009). Cancer statistics, 2009. CA Cancer J Clin 59, 225-249.
- Kang, J.H., Lee, S.I., Lim do, H., Park, K.W., Oh, S.Y., Kwon, H.C., Hwang, I.G., Lee, S.C., Nam, E., Shin, D.B., *et al.* (2012). Salvage chemotherapy for pretreated gastric cancer: a randomized phase III trial comparing chemotherapy plus best supportive care with best supportive care alone. J Clin Oncol 30, 1513-1518.
- Kelsen, D.P., Winter, K.A., Gunderson, L.L., Mortimer, J., Estes, N.C., Haller, D.G., Ajani, J.A., Kocha, W., Minsky, B.D., Roth, J.A., *et al.* (2007). Long-term results of RTOG trial 8911 (USA Intergroup 113): a random assignment trial comparison of chemotherapy followed by surgery compared with surgery alone for esophageal cancer. J Clin Oncol 25, 3719-3725.
- Kudo, M., Imanaka, K., Chida, N., Nakachi, K., Tak, W.Y., Takayama, T., Yoon, J.H., Hori, T., Kumada, H., Hayashi, N., *et al.* (2011). Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer 47, 2117-2127.
- Lagergren, J., and Lagergren, P. (2013). Recent developments in esophageal adenocarcinoma. CA Cancer J Clin 63, 232-248.
- Llovet, J.M., Ricci, S., Mazzaferro, V., Hilgard, P., Gane, E., Blanc, J.F., de Oliveira, A.C., Santoro, A., Raoul, J.L., Forner, A., *et al.* (2008). Sorafenib in advanced hepatocellular carcinoma. The New England journal of medicine 359, 378-390.
- Ma, J.L., Zhang, L., Brown, L.M., Li, J.Y., Shen, L., Pan, K.F., Liu, W.D., Hu, Y., Han, Z.X., Crystal-Mansour, S., *et al.* (2012). Fifteen-year effects of Helicobacter pylori, garlic, and vitamin treatments on gastric cancer incidence and mortality. J Natl Cancer Inst 104, 488-492.
- Noh, S.H., Park, S.R., Yang, H.K., Chung, H.C., Chung, I.J., Kim, S.W., Kim, H.H., Choi, J.H., Kim, H.K., Yu, W., *et al.* (2014). Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. The Lancet Oncology 15, 1389-1396.
- Ono, T., Yamanoi, A., Nazmy El Assal, O., Kohno, H., and Nagasue, N. (2001). Adjuvant chemotherapy after resection of hepatocellular carcinoma causes deterioration of long-term prognosis in cirrhotic patients: metaanalysis of three randomized controlled trials. Cancer 91, 2378-2385.
- Park, J.W., Chen, M., Colombo, M., Roberts, L.R., Schwartz, M., Chen, P.J., Kudo, M., Johnson, P., Wagner, S., Orsini, L.S., *et al.* (2015a). Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int 35, 2155-2166.

- Park, S.H., Sohn, T.S., Lee, J., Lim, D.H., Hong, M.E., Kim, K.M., Sohn, I., Jung, S.H., Choi, M.G., Lee, J.H., *et al.* (2015b). Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*.
- Pohl, H., and Welch, H.G. (2005). The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. *J Natl Cancer Inst* 97, 142-146.
- Shaheen, N.J., Weinberg, D.S., Denberg, T.D., Chou, R., Qaseem, A., and Shekelle, P. (2012). Upper endoscopy for gastroesophageal reflux disease: best practice advice from the clinical guidelines committee of the American College of Physicians. *Ann Intern Med* 157, 808-816.
- Smalley, S.R., Benedetti, J.K., Haller, D.G., Hundahl, S.A., Estes, N.C., Ajani, J.A., Gunderson, L.L., Goldman, B., Martenson, J.A., Jessup, J.M., *et al.* (2012). Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 30, 2327-2333.
- Songun, I., Putter, H., Kranenbarg, E.M., Sasako, M., and van de Velde, C.J. (2010). Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. *The Lancet Oncology* 11, 439-449.
- Stahl, M., Stuschke, M., Lehmann, N., Meyer, H.J., Walz, M.K., Seeber, S., Klump, B., Budach, W., Teichmann, R., Schmitt, M., *et al.* (2005). Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. *J Clin Oncol* 23, 2310-2317.
- Syngal, S., Brand, R.E., Church, J.M., Giardiello, F.M., Hampel, H.L., and Burt, R.W. (2015). ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. *The American journal of gastroenterology* 110, 223-262; quiz 263.
- Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., and Jemal, A. (2015). Global cancer statistics, 2012. *CA Cancer J Clin* 65, 87-108.
- van Hagen, P., Hulshof, M.C., van Lanschot, J.J., Steyerberg, E.W., van Berge Henegouwen, M.I., Wijnhoven, B.P., Richel, D.J., Nieuwenhuijzen, G.A., Hospers, G.A., Bonenkamp, J.J., *et al.* (2012). Preoperative chemoradiotherapy for esophageal or junctional cancer. *The New England journal of medicine* 366, 2074-2084.
- Wilke, H., Muro, K., Van Cutsem, E., Oh, S.C., Bodoky, G., Shimada, Y., Hironaka, S., Sugimoto, N., Lipatov, O., Kim, T.Y., *et al.* (2014). Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. *The Lancet Oncology*.
- Ychou, M., Boige, V., Pignon, J.P., Conroy, T., Bouche, O., Lebreton, G., Ducourtieux, M., Bedenne, L., Fabre, J.M., Saint-Aubert, B., *et al.* (2011). Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 29, 1715-1721.